Agenus (AGEN) Stock Price, News & Analysis

Company Overview

Agenus, Inc. (NASDAQ: AGEN) is a biotechnology company focused on the discovery and development of immuno-oncology therapies and vaccine adjuvants. Originally founded as Antigenics, Inc. in 1994, the company adopted the Agenus name in 2014 to reflect its expanded platform capabilities. Headquartered in Lexington, Massachusetts, Agenus combines proprietary antibody discovery technologies with novel checkpoint modulation approaches to address the challenges of cancer treatment and infectious diseases.

The company’s core business activities center on its QUILT™ platform, which integrates high-throughput antibody discovery, humanization, and engineering to generate fully human monoclonal antibodies. Agenus specializes in checkpoint modulators that target proteins such as CTLA-4, PD-1 and LAG-3 to enhance T-cell activity against tumors. In addition to its therapeutic pipeline, Agenus is a recognized provider of QS-21 Stimulon® adjuvant, a saponin-based vaccine enhancer licensed by global vaccine developers for use in oncology and prophylactic vaccine candidates.

Agenus maintains a global footprint through collaborations and partnerships with leading pharmaceutical and biotechnology companies in North America, Europe and Asia. Its agreements include research and development collaborations, license arrangements and co-development programs aimed at accelerating the translation of novel immunotherapies into clinical trials. The company also operates cGMP manufacturing facilities in the United States, supporting both its internal vaccine adjuvant supply and third-party partnerships.

Led by co-founder and Executive Chairman Garo H. Armen, Agenus is governed by an experienced management team with deep expertise in drug discovery, clinical development and commercial strategy. The leadership team includes veterans in oncology research, translational medicine and biomanufacturing, positioning the company to advance its pipeline through key clinical milestones and regulatory filings.

Key Stats

• Today's Range: $6.12 to $6.71
• 50-Day Range: $3.02 to $7.06
• 52-Week Range: $1.38 to $7.34
• Volume: 1.08 million shs
• Average Volume: 706,643 shs
• Market Capitalization: $168.63 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $14.00
• Consensus Rating: Hold

Agenus Stock Analysis - MarketRank™

Agenus scored higher than 85% of companies evaluated by MarketBeat, and ranked 157th out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

Agenus has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 2 buy ratings, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Agenus has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Agenus are expected to grow in the coming year, from ($12.55) to ($7.16) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Agenus is -0.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Agenus is -0.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

9.73% of the float of Agenus has been sold short.

Short Interest Ratio / Days to Cover

Agenus has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Agenus has recently decreased by 20.56%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Agenus does not currently pay a dividend.

Dividend Growth

Agenus does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.6 / 5
• Environmental Score: -0.93

Percentage of Shares Shorted

9.73% of the float of Agenus has been sold short.

Short Interest Ratio / Days to Cover

Agenus has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Agenus has recently decreased by 20.56%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.86

News Sentiment

Agenus has a news sentiment score of 0.86. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.96 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Agenus this week, compared to 6 articles on an average week.

Search Interest

19 people have searched for AGEN on MarketBeat in the last 30 days. This is an increase of 6% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Agenus insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 5.50% of the stock of Agenus is held by insiders.

Percentage Held by Institutions

61.46% of the stock of Agenus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

AGEN Stock Analysis - Frequently Asked Questions

How have AGEN shares performed this year?

Agenus' stock was trading at $2.74 on January 1st, 2025. Since then, AGEN shares have increased by 124.5% and is now trading at $6.15.

How were Agenus' earnings last quarter?

Agenus Inc. (NASDAQ:AGEN) posted its earnings results on Monday, May, 12th. The biotechnology company reported ($1.03) EPS for the quarter, beating analysts' consensus estimates of ($1.61) by $0.58. The biotechnology company earned $24.07 million during the quarter, compared to analyst estimates of $26.38 million.
Read the conference call transcript.

When did Agenus' stock split?

Agenus shares reverse split on Friday, April 12th 2024.The 1-20 reverse split was announced on Friday, April 12th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, April 12th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Who are Agenus' major shareholders?

Top institutional shareholders of Agenus include Key Client Fiduciary Advisors LLC (0.14%) and Wealth Enhancement Advisory Services LLC (0.07%). Insiders that own company stock include Agenus Inc and Garo H Armen.
View institutional ownership trends.

How do I buy shares of Agenus?

Shares of AGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Agenus own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Agenus investors own include DiamondRock Hospitality (DRH), Waste Connections (WCN), American Water Works (AWK), Voyager Therapeutics (VYGR), The RMR Group (RMR), AU Optronics (AUOTY) and iShares Micro-Cap ETF (IWC).

Company Calendar

• Last Earnings: 5/12/2025
• Today: 7/18/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:AGEN
• CIK: 1098972
• Web: agenusbio.com
• Phone: (781) 674-4400
• Fax: 781-674-4200
• Employees: 440
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Agenus: $14.00
• High Price Target: $25.00
• Low Price Target: $6.00
• Potential Upside/Downside: +122.8%
• Consensus Rating: Hold
• Rating Score (0-4): 2.40
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($8.67)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$227.21 million
• Net Margins: -196.12%
• Pretax Margin: -196.12%
• Return on Equity: N/A
• Return on Assets: -82.33%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.11
• Quick Ratio: 0.11

Sales & Book Value

• Annual Sales: $103.46 million
• Price / Sales: 1.67
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($13.06) per share
• Price / Book: -0.48

Miscellaneous

• Outstanding Shares: 27,420,000
• Free Float: 25,909,000
• Market Cap: $172.33 million
• Optionable: Optionable
• Beta: 1.51